Page 138 - TD-3-4

Tumor Discovery CTC characterization for EGFR mutations

patients with uncommon EGFR mutations: New insights response to tyrosine kinase inhibitors. Transl Lung Cancer
and future perspectives in this complex clinical scenario. Int Res. 2020;12(9):4643-4650.
J Mol Sci. 2019;20:1431.
doi: 10.21037/jtd-19-3790
doi: 10.3390/ijms20061431
16. Byeon S, Kim Y, Lim SW, et al. Clinical outcomes of EGFR
7. Janne P, Wang X, Sociniski M, et al. Randomized phase II exon 20 insertion mutations in advanced non-small cell lung
trial of erlotinib alone or with carboplatin and paclitaxel cancer in Korea. Cancer Res Treat. 2019;51(2):623-631.
in patients who were never or light former smokers with doi: 10.4143/crt.2018.151
advanced lung adenocarcinoma. CALGB30406 trial. J Clin
Oncol. 2012;30(17):2063-2069. 17. Ou SI, Lin HM, Hong JL, et al. Real-world response and
outcomes in patients with NSCLC with EGFR exon 20
doi: 10.1200/JCO.2011.40.1315
insertion mutations. JTO Clin Res Rep. 2023;4(10):100558.
8. Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus doi: 10.1016/j.jtocrr.2023.100558
gemcitabine/cisplatin in patients with advanced EGFR
mutation-positive non-small-cell lung cancer: Analyses 18. Vaclova T, Grazini U, Ward L, et al. Clinical impact of
from the phase III, randomized, open-label, ENSURE study. subclonal EGFR T790M mutations in advanced-stage
Ann Oncol. 2015;26:1883-1889. EGFR-mutant non-small-cell lung cancers. Nat Commun.
2021;12:1780.
doi: 10.1093/annonc/mdv270
doi: 10.1038/s41467-021-22057-8
9. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-
based chemotherapy for EGFR mutation-positive lung 19. Bencze E, Bogos K, Kohánka A, et al. EGFR T790M mutation
adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis detection in patients with non-small cell lung cancer after
of overall survival data from two randomized, phase 3 trials. first line EGFR TKI therapy: Summary of results in a three-
Lancet Oncol. 2015;16(2):141-151. year period and a comparison of commercially available
detection kits. Pathol Oncol Res. 2022;28:1610607.
doi: 10.1016/S1470-2045(14)71173-8
doi: 10.3389/pore.2022.1610607
10. Costa DB. Kinase inhibitor-responsive genotypes in EGFR
mutated lung adenocarcinomas: Moving past common 20. Zhao Z, Li L, Wang Z, Duan J, Bai H, Wang J. The status of the
point mutations or indels into uncommon kinase domain EGFR T790M mutation is associated with the clinical benefits
duplications and rearrangements. Transl Lung Cancer Res. of osimertinib treatment in non-small cell lung cancer
2016;5:331-337. patients: A meta-analysis. J Cancer. 2020;11(11):3106-3113.
doi: 10.21037/tlcr.2016.06.04 doi: 10.7150/jca.38411
11. Xu H, Yang G, Li W, et al. EGFR exon 18 mutations in 21. Araki T, Kanda S, Horinouchi H, Ohe Y. Current treatment
advanced non-small cell lung cancer: A real-world study strategies for EGFR-mutated non-small cell lung cancer:
on diverse treatment patterns and clinical outcomes. Front From first line to beyond osimertinib resistance. Jpn J Clin
Oncol. 2021;11:713483. Oncol. 2023;53(7):547-561.
doi: 10.3389/fonc.2021.713483 doi: 10.1093/jjco/hyad052
12. Rossi S, D’Argento E, Basso M, et al. Different EGFR gene 22. Attili I, Passaro A, Pisapia P, Malapelle U, de Marinis F.
mutations in exon 18, 19 and 21 as prognostic and predictive Uncommon EGFR compound mutations in non-small cell
markers in NSCLC: A single institution analysis. Mol Diagn lung cancer (NSCLC): A systematic review of available
Ther. 2016;20(1):55-63. evidence. Curr Oncol. 2022;29(1):255-266.
doi: 10.1007/s40291-015-0176-x doi: 10.3390/curroncol29010024
13. Klughammer B, Brugger W, Cappuzzo F, et al. Examining 23. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular
treatment outcomes with erlotinib in patients with advanced testing guideline for the selection of patients with lung
non-small cell lung cancer whose tumors harbor uncommon cancer for treatment with targeted tyrosine kinase inhibitors:
EGFR mutations. J Thorac Oncol. 2016;11:545-555. American Society of Clinical Oncology Endorsement of the
College of American Pathologists/International Association
doi: 10.1016/j.jtho.2015.12.107
for the Study of Lung Cancer/Association for Molecular
14. Zhang T, Wan B, Zhao Y, et al. Treatment of uncommon Pathology Clinical Practice Guideline Update. J Clin Oncol.
EGFR mutations in non-small cell lung cancer: New evidence 2018;36:911-919.
and treatment. Transl Lung Cancer Res. 2019;8(3):302-316.
doi: 10.1200/JCO.2017.76.7293
doi: 10.21037/tlcr.2019.04.12
24. Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines

15. Brindel A, Althakafi W, Barritault M, et al. Uncommon insights: Non-small cell lung cancer. J Natl Compr Canc
EGFR mutations in lung adenocarcinoma: Features and Netw. 2023;21(4):340-350.

Volume 3 Issue 4 (2024) 14 doi: 10.36922/td.3987